前收市價 | 13.30 |
開市 | 13.30 |
買盤 | 11.10 |
賣出價 | 12.20 |
拍板 | 17.50 |
到期日 | 2024-06-21 |
今日波幅 | 13.30 - 13.30 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 46 |
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.